GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
This article was originally published in PharmAsia News
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.
You may also be interested in...
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
SHANGHAI - While Beijing is hosting China's National People's Congress this week to discuss and design its next Five-Year Plan, China's powerful National Development and Reform Commission announced another round of price cuts on antibiotics and cardiovascular drugs with an average price reduction of 21%, less than the rumored 30-40% cuts, but still a blow to Big Pharma
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies